Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a defined frequency of 5 Hz-500 kHz and a field strength of 0.1-5000 ?T to a target body area that includes the cancer or other rapidly-dividing cells, and modifying the cancer or tumor microenvironment to increase the presence of cancer-suppressive cells or decrease the presence of cancer-promoting cells. In various embodiments, the systems and methods may include adjusting the therapy based on the dosage of an immunotherapy drug administered to the patient before, during, or after the application of the AP magnetic fields.

Abstract: Systems for destroying or inhibiting cancer cells and other rapidly-dividing cells including an alternating polarity (AP) magnetic field generator and at least one AP electromagnetic coil adapted to be coupled to a target body area, and a controller to control the AP magnetic field generator and at least one AP electromagnetic coil and cause the field generator and coil to apply AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.

Abstract: Systems for destroying or inhibiting cancer cells and other rapidly-dividing cells including an alternating polarity (AP) magnetic field generator and at least one AP electromagnetic coil adapted to be coupled to a target body area, and a controller to control the AP magnetic field generator and at least one AP electromagnetic coil and cause the field generator and coil to apply AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.

Abstract: Adjustable auricular nerve stimulation devices, and associated systems and methods, are disclosed herein. A representative device for delivering an electrical signal to a subject includes a signal delivery element including at least two electrodes configured to deliver the electrical signal to a first portion of the subject’s ear. The device also includes a retention element configured to engage a second portion of the subject’s ear. The device further includes an adjustment mechanism permitting movement of the signal delivery element relative to the retention element to place the at least two electrodes in contact with the first portion of the subject’s ear.

Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a defined frequency of 5 Hz-500 kHz and a field strength of 0.1-5000 ?T to a target body area that includes the cancer or other rapidly-dividing cells, and modifying the cancer or tumor microenvironment to increase the presence of cancer-suppressive cells or decrease the presence of cancer-promoting cells. In various embodiments, the systems and methods may include adjusting the therapy based on the dosage of an immunotherapy drug administered to the patient before, during, or after the application of the AP magnetic fields.

Abstract: Auricular nerve stimulation techniques for addressing patient disorders, and associated systems and methods. A representative system includes a signal generator having instructions to generate an electrical therapy signal, at least a portion of the electrical therapy signal having a frequency at or above the patient's auditory frequency limit, an amplitude in an amplitude range from about 0.1 mA to about 10 mA, and a pulse width in a pulse width range from 5 microseconds to 30 microseconds. The system further includes at least one earpiece having a contoured outer surface shaped to fit against the skin of the patient's external ear, external ear canal, or both, the at least one earpiece carrying at least two transcutaneous electrodes positioned to be in electrical communication with the auricular innervation of the patient, e.g., the auricular vagal nerve.

Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a defined frequency of 5 Hz-500 kHz and a field strength of 0.1-5000 ?T to a target body area that includes the cancer or other rapidly-dividing cells, and modifying the cancer or tumor microenvironment to increase the presence of cancer-suppressive cells or decrease the presence of cancer-promoting cells. In various embodiments, the systems and methods may include adjusting the therapy based on the dosage of an immunotherapy drug administered to the patient before, during, or after the application of the AP magnetic fields.

Abstract: Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells include coupling an alternating polarity (AP) magnetic field generator to a target body area and applying an AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.

Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a defined frequency of 5 Hz-500 kHz and a field strength of 0.1-5000 ?T to a target body area that includes the cancer or other rapidly-dividing cells, and modifying the cancer or tumor microenvironment to increase the presence of cancer-suppressive cells or decrease the presence of cancer-promoting cells. In various embodiments, the systems and methods may include adjusting the therapy based on the dosage of an immunotherapy drug administered to the patient before, during, or after the application of the AP magnetic fields.

Abstract: Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells include coupling an alternating polarity (AP) magnetic field generator to a target body area and applying an AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.

Abstract: Auricular nerve stimulation techniques for addressing patient disorders, and associated systems and methods. A representative system includes a signal generator having instructions to generate an electrical therapy signal, at least a portion of the electrical therapy signal having a frequency at or above the patient's auditory frequency limit, an amplitude in an amplitude range from about 0.1 mA to about 10 mA, and a pulse width in a pulse width range from 5 microseconds to 30 microseconds. The system further includes at least one earpiece having a contoured outer surface shaped to fit against the skin of the patient's external ear, external ear canal, or both, the at least one earpiece carrying at least two transcutaneous electrodes positioned to be in electrical communication with the auricular innervation of the patient, e.g., the auricular vagal nerve.

Abstract: The present disclosure relates to devices and methods for stimulating peripheral nerves in a patient via electrical, optical, mechanical, or other stimulation, in order to change the balance between parasympathetic and sympathetic activity by selectively increasing or decreasing each of parasympathetic and sympathetic activity. In a particular application, the present disclosure relates to a device for transdermal stimulation of the vagus nerve (including the auricular branch) to selectively affect the sympathetic and parasympathetic nervous system to achieve the desired therapeutic effect in a human subject.

Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a defined frequency of 5 Hz-500 kHz and a field strength of 0.1-5000 ?T to a target body area that includes the cancer or other rapidly-dividing cells, and modifying the cancer or tumor microenvironment to increase the presence of cancer-suppressive cells or decrease the presence of cancer-promoting cells. In various embodiments, the systems and methods may include adjusting the therapy based on ultrasound imaging of the cancer cells during the application of the AP magnetic fields or during a cessation of applying the AP magnetic fields.

Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to a target body area that includes the cancer or other rapidly-dividing cells.

Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a defined frequency of 5 Hz-500 kHz and a field strength of 0.1-5000 ?T to a target body area that includes the cancer or other rapidly-dividing cells, and modifying the cancer or tumor microenvironment to increase the presence of cancer-suppressive cells or decrease the presence of cancer-promoting cells. In various embodiments, the systems and methods may include adjusting the therapy based on ultrasound imaging of the cancer cells during the application of the AP magnetic fields or during a cessation of applying the AP magnetic fields.

Abstract: The present disclosure relates to devices and methods for stimulating peripheral nerves in a patient via electrical, optical, mechanical, or other stimulation, in order to change the balance between parasympathetic and sympathetic activity by selectively increasing or decreasing each of parasympathetic and sympathetic activity. In a particular application, the present disclosure relates to a device for transdermal stimulation of the vagus nerve (including the auricular branch) to selectively affect the sympathetic and parasympathetic nervous system to achieve the desired therapeutic effect in a human subject.

Abstract: Auricular nerve stimulation techniques for addressing patient disorders, and associated systems and methods. A representative system includes a signal generator having instructions to generate an electrical therapy signal, at least a portion of the electrical therapy signal having a frequency at or above the patient's auditory frequency limit, an amplitude in an amplitude range from about 0.1 mA to about 10 mA, and a pulse width in a pulse width range from 5 microseconds to 30 microseconds. The system further includes at least one earpiece having a contoured outer surface shaped to fit against the skin of the patient's external ear, external ear canal, or both, the at least one earpiece carrying at least two transcutaneous electrodes positioned to be in electrical communication with the auricular innervation of the patient, e.g., the auricular vagal nerve.

Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to a target body area that includes the cancer or other rapidly-dividing cells.

Abstract: Auricular nerve stimulation techniques for modulating brain function of a person and/or improving the person's wellness, and associated systems and methods, are provided. A representative system includes a signal generator having instructions to generate an electrical signal, at least a portion of the electrical signal having a frequency at or above the person's auditory frequency limit, an amplitude in an amplitude range from about 0.1 mA to about 10 mA, and a pulse width in a pulse width range from 5 microseconds to 30 microseconds. The system further includes at least one earpiece having a contoured outer surface shaped to fit against the skin of the person's external ear, external ear canal, or both, the at least one earpiece carrying at least two transcutaneous electrodes positioned to be in electrical communication with the auricular innervation of the person, e.g., the auricular vagal nerve.

Abstract: Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include coupling an alternating polarity (AP) magnetic field generator to a target body area and applying an AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.